Study on V940 and Pembrolizumab for People with High-Risk Melanoma

Sponsor: Merck Sharp & Dohme LLC

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05933577

Provider View

This clinical trial is testing whether a new treatment, V940, combined with pembrolizumab, can safely prevent melanoma from returning in people at high risk. The study aims to find out if this combination is more effective than pembrolizumab alone.

Patient Parameters

Program Overview

The goal of this study is to determine if a new treatment called V940, when used with pembrolizumab, is safe and can help stop melanoma from coming back in people who are at high risk. Researchers want to see if this combination works better than just using pembrolizumab by itself.

Eligibility Criteria

Inclusion Criteria

  • Have had surgery to remove melanoma and have a confirmed diagnosis of Stage IIB, IIC, III, or IV skin melanoma.
  • Have not received any other treatments for melanoma besides surgery.
  • No more than 13 weeks have passed since the last surgery that removed all cancer.
  • Be free of cancer at the time of joining the study.
  • If HIV-positive, must have well-controlled HIV with medication.

Exclusion Criteria

  • Have melanoma in the eye or mucous membranes.
  • Have cancer that has spread and cannot be removed by surgery.
  • Have had heart failure in the last 6 months.
  • Have received previous cancer treatments or vaccines.
  • Have another cancer that has spread or needed treatment in the last 3 years.
  • Have had severe reactions to study drugs or their ingredients.
  • Have not fully recovered from major surgery or have ongoing surgical issues.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.